drugset
Drugs / Recombinant SARS-CoV-2 Ad5 vectored vaccine
last change Mar 2023 re-read 3 minutes ago

Recombinant SARS-CoV-2 Ad5 vectored vaccine

also known as Convidecia

Vaccine

Developed for
COVID-19
Investigated by
CanSino Biologics Inc. · Jiangsu Province Centers for Disease Control and Prevention

Trials 1

today NCT04892459 · Ph 4
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04892459 May → Jul 2021 COVID-19 Jiangsu Province Centers for Disease Control and Prevention Completed Mixed

Press releases naming this drug 12 releases

DateIssuerRelease
2023-03-02 CanSino Biologics Inc. CanSinoBIO's Convidecia Air® Receives Approval in Indonesia cansinotech.com ↗
2022-12-27 CanSino Biologics Inc. First Overseas Shipment of CanSinoBIO’s Convidecia Air™ Delivered to Morocco cansinotech.com ↗
2022-11-10 CanSino Biologics Inc. CanSinoBIO’s Convidecia Air™ Approved for Emergency Use in Morocco cansinotech.com ↗
2022-10-25 CanSino Biologics Inc. CanSino Biologics Celebrates the Rollout of the Inhaled Vaccine, Convidecia Air™, in Shanghai cansinotech.com ↗
2022-10-06 CanSino Biologics Inc. CanSinoBIO to Present Latest Data on Convidecia Air™ at the World Vaccine Congress Europe 2022 cansinotech.com ↗
2022-09-04 CanSino Biologics Inc. CanSinoBIO's Convidecia Air™ Receives Approval in China cansinotech.com ↗
2022-08-18 CanSino Biologics Inc. Convidecia Air™ Receives Clinical Trial Approval in Malaysia cansinotech.com ↗
2022-05-20 CanSino Biologics Inc. COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing cansinotech.com ↗
2022-03-22 CanSino Biologics Inc. CanSinoBIO's Convidecia Approved as Heterologous Booster in Malaysia and Indonesia cansinotech.com ↗
2022-03-14 CanSino Biologics Inc. Latest Study Shows Advantages of CanSinoBIO’s Convidecia as Heterologous Booster against Omicron Variant cansinotech.com ↗
2022-02-20 CanSino Biologics Inc. Convidecia Approved as Heterologous Booster in China cansinotech.com ↗
2021-12-23 CanSino Biologics Inc. Convidecia™ Phase III Results Published in The Lancet cansinotech.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Recombinant SARS-CoV-2 Ad5 vectored vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04892459 ↗
Known as Convidecia “We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac...” PMID 35087233 ↗ Jan 2022
Modality Vaccine “the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia” PMID 35087233 ↗ Jan 2022